Results 1 to 10 of about 1,296,096 (233)
Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor [PDF]
Pharmacology Research & Perspectives, 2023 The rapid structural evolution and emergence of novel synthetic cannabinoid receptor agonists (SCRAs) in the recreational market remains a key public health concern.
Monica Patel +4 more
doaj +4 more sources
Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG‐018 [PDF]
Pharmacology Research & Perspectives, 2022 Neutral antagonists of GPCRs remain relatively rare—indeed, a large majority of GPCR antagonists are actually inverse agonists. The synthetic cannabinoid receptor agonist (SCRA) EG‐018 was recently reported as a low efficacy cannabinoid receptor agonist.
David B. Finlay +9 more
doaj +3 more sources
Molecules, 2022 1,8-naphthyridine-3-carboxamide structures were previously identified as a promising scaffold from which to obtain CB2R agonists with anticancer and anti-inflammatory activity.
Francesca Gado +12 more
doaj +3 more sources
Cells, 2023 Cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2) are components in the endocannabinoid system that play significant roles in regulating immune responses. There are many agonists for the cannabinoid receptors; however, their effects on T cell
Nuchjira Takheaw +4 more
doaj +1 more source
Endocannabinoids in Bladder Sensory Mechanisms in Health and Diseases
Frontiers in Pharmacology, 2021 The recent surge in research on cannabinoids may have been fueled by changes in legislation in several jurisdictions, and by approval for the use of cannabinoids for treatment of some chronic diseases. Endocannabinoids act largely, but not exclusively on
Stewart Christie +2 more
doaj +1 more source
Cannabinoid and Cannabinoid-Related Receptors in the Myenteric Plexus of the Porcine Ileum
Animals, 2021 An important piece of evidence has shown that molecules acting on cannabinoid receptors influence gastrointestinal motility and induce beneficial effects on gastrointestinal inflammation and visceral pain.
Andrea Toschi +6 more
doaj +1 more source
Heliyon, 2021 The identification of cannabinoid ligands Cannabidiol and O-1918 as inverse agonists of the orphan receptor GPR52 is reported. Detailed characterisation of GPR52 pharmacology and modelling of the proposed receptor interaction is described.
Lisa A. Stott +12 more
doaj +1 more source
Cannabichromene is a cannabinoid CB 2 receptor agonist [PDF]
British Journal of Pharmacology, 2018 Background and Purpose Cannabichromene (CBC) is one of the most abundant phytocannabinoids in Cannabis spp . It has modest antinociceptive and anti‐inflammatory effects and potentiates some effects of Δ 9
Udoh, Michael +4 more
openaire +2 more sources
Pharmacology Research & Perspectives, 2022 Sexual dimorphisms are observed in cannabinoid pharmacology. It is widely reported that female animals are more sensitive to the cataleptic, hypothermic, antinociceptive, and anti‐locomotive effects of cannabinoid receptor agonists such as CP55,940 ...
Hye Ji J. Kim +5 more
doaj +1 more source
CB1 Cannabinoid Receptor Signaling and Biased Signaling
Molecules, 2021 The CB1 cannabinoid receptor is a G-protein coupled receptor highly expressed throughout the central nervous system that is a promising target for the treatment of various disorders, including anxiety, pain, and neurodegeneration.
Luciana M. Leo, Mary E. Abood
doaj +1 more source